Sartorius Stedim Biotech SA (DIM), with a market capitalization of $135.93 million, reported robust earnings for the first quarter of 2025, exceeding analyst expectations with an earnings per ...

Sales revenue at 745 million euros, up 10.4 percent in constant currencies 1 (reported: 11.7 percent) Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, started the fiscal ...

Sales revenue at 745 million euros, up 10.4 percent in constant currencies 1 (reported: 11.7 percent) Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, started the ...

About Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Jan 28 (Reuters) - Shares in Sartorius (SATG.DE), opens new tab jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a ...

=----- Sartorius Stedim Biotech S.A. - 13400 Aubagne, France DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Article L 233-8-II of the Code of commerce ...

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts. This state-of-the-art facility is designed ...

In 2025, Sartorius Stedim Biotech will add two multi-modality GMP suites, operating on Sartorius workflows and equipment. The suites will allow customers to extend their process development ...

Sartorius Stedim Biotech, the bioprocess subsidiary of Sartorius AG, is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. Sartorius performs ...